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Abstract 
 
The de novo ceramide synthesis pathway is essential to human biology and health but genetic influences 
remain unexplored. The core function of this pathway is the generation of biologically active ceramide from 
its precursor, dihydroceramide. Dihydroceramides have diverse, often protective, biological roles; 
conversely, increased ceramide levels are biomarkers of complex disease. To explore the genetics of the 
ceramide synthesis pathway, we searched for deleterious nonsynonymous variants in the genomes of 1,020 
Mexican Americans from extended pedigrees. We identified a Hispanic ancestry−specific rare functional 
variant, L175Q, in DEGS1, a key enzyme in the pathway that converts dihydroceramide to ceramide. This 
amino acid change was significantly associated with large increases in plasma dihydroceramides. Indexes 
of DEGS1 enzymatic activity were dramatically reduced in heterozygotes. CRISPR/Cas9 genome editing 
of HepG2 cells confirmed that the L175Q variant results in a partial loss of function for the DEGS1 enzyme. 
Understanding the biological role of DEGS1 variants, such as L175Q, in ceramide synthesis may improve 
the understanding of metabolic-related disorders, and spur ongoing research of drug targets along this 
pathway. 
 
Keywords: Lipidomics, Ceramides, Sphingolipids, Genomics, Genetics 
 
 at University of Tasm
ania Library, on O
ctober 1, 2019
w
w
w
.jlr.org
D
ow
nloaded from
 
 4 
Introduction 
The classical lipid parameters (such as high-density lipoprotein cholesterol (HDL-C), low-density 
lipoprotein cholesterol (LDL-C), triglycerides (TG) and total cholesterol) that are most commonly 
examined in relation to disease risk are themselves complex entities composed of multiple lipid and protein 
components. The lipidome, defined as the total lipid complement of a given biological system, contains 
many thousands of these individual lipid species and represents a wealth of phenotypes that might serve as 
better predictors of disease than more complex lipoproteins. The biologically simpler nature of individual 
lipid species suggests that their phenotypic variation lies closer to the genomic level and ultimately the 
causal action of genes, making them valuable endophenotypes (1, 2). Our studies have shown that specific 
lipoproteins and indeed their constituent lipids are as heritable as the classic lipoprotein measures that have 
dominated disease epidemiology and are important factors in the development of disease (3-9). The field 
of lipidomics has received increasing attention in recent years with several studies highlighting the 
relationships between individual lipid species and health outcomes in both disease based cohorts and in 
healthy population cohort studies (10, 11). In particular, circulating levels of particular ceramide species 
are being considered as clinical biomarkers for cardiometabolic disease (12). 
 
Ceramides are a family of lipid molecules that consist of a sphingosine covalently linked to a fatty acid acyl 
chain, with species differing by length, hydroxylation, and saturation of the sphingoid base and fatty acid 
moieties. Ceramide production occurs through three major pathways: de novo ceramide synthesis, 
sphingomyelin synthesis and the ceramide salvage pathway. Both the sphingomyelin synthesis and 
ceramide salvage pathways require ceramide initially for activation; with the sphingomyelin pathway 
generating ceramide through the hydrolysis of sphingomyelin, and the salvage pathway through the 
catabolism of other sphingolipids. In contrast, the de novo synthesis pathway depends on the availability of 
palmitate and serine to synthesize dihydroceramide (which is converted to ceramide) through a series of 
enzymatic reactions (13). 
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Levels of individual dihydroceramide and ceramide species, and ratios between species, have been 
implicated in cardiovascular and metabolic disease. First thought to be biologically inert dihydroceramides 
have now been shown to have diverse roles in autophagy, apoptosis, infection and metabolic disease, with 
increases in dihydroceramide levels generally protective (reviewed in Siddique et al. (2015) (14)), however 
Wigger et al. have shown in two human cohorts that increased dihydroceramide levels are associated with 
future development of type 2 diabetes (T2D), challenging the protective role assigned to dihydroceramides 
(15). Evidence through previous work from our group also challenges the protective role of 
dihydroceramides. We developed a lipidomic risk score that identified, with two other lipid species, 
increased levels of the dihydroceramide species Cer(d18:0/18:0) as a predictive factor for future T2D 
development (9). The addition of a double bond to the chemical structure of dihydroceramides, by the 
enzyme DEGS1, produces ceramides. In contrast to dihydroceramides, increases in levels of ceramides is 
repeatedly shown to be linked to cardiovascular disease, particular ceramide species Cer(d18:1/16:0), 
Cer(d18:1/20:0) and Cer(d18:1/24:1) (16, 17). As there is a clear link to disease demonstrated in both 
disease based and healthy cohorts a new avenue to understand the relationship between ceramide biology 
and disease is to identify genetic variation underlying variation in levels of individual ceramide biology 
lipid species.  
 
Here, in the first human genomic study of ceramide synthesis, using targeted lipidomic profiles and whole 
genome sequence (WGS) in 1,020 Mexican Americans from 46 large extended pedigrees of the San 
Antonio Family Heart Study (SAFHS), we searched for nonsynonymous variants, predicted to be 
deleterious, influencing ceramides and related lipid species. Within our lipidomic profiles, (previously 
described (5-9)) we have measures of six dihydroceramide species and six ceramide species. We use these 
12 lipid species as a gateway to investigate the genetics of the ceramide synthesis pathway.  
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Materials and Methods 
Study Participants 
The San Antonio Family Heart Study (SAFHS) began in 1991 and was initially designed to investigate the 
genetics of CVD in Mexican American individuals. The SAFHS enrolled large, extended Mexican 
American families residing in San Antonio and ascertainment occurred by way of the random selection of 
an adult Mexican American proband, without regard to disease. The enrollment procedures, inclusion and 
exclusion criteria, and phenotypic assessments of the study participants have been described in detail 
previously (18, 19). This is an ongoing investigation which has had four phases of data collection over a 25 
year period. The data and samples used in this study were collected during the first phase of data collection, 
occurring between 1992 and 1996. For the 1,020 SAFHS participants specifically used in this study 61.8% 
were female, and the sample was aged between 15 and 94 (mean=39.8). Informed consent was obtained 
from all participants before collection of samples. The study conformed to the Declaration of Helsinki and 
the Institutional Review Boards of the University of Texas Health Sciences Center at San Antonio and the 
University of Texas Rio Grande Valley have approved this study.  
 
Lipidomic Profiling 
Plasma concentrations of 319 lipid species (representing 23 lipid classes) were measured in 1,212 
participants from the first visit of SAFHS using electrospray ionization-tandem mass spectrometry (ESI-
MS/MS) quantification. Lipidomic profiling was performed in the Metabolomics Laboratory, Baker Heart 
and Diabetes Institute, Melbourne, Australia. The experimental protocols used have been described 
elsewhere (5, 20). In the current study 1,020 individuals have both lipidome profiles and whole genome 
sequence data.  
 
Genome Sequencing and SNP array genotyping 
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 7 
In the currently available data from the original San Antonio Family Heart Study, 1,514 individuals have 
whole genome sequence available for analysis. Whole genome sequencing for 496 individuals in this study 
was performed by Complete Genomics at 50x coverage (21) as part of the T2D-GENES consortium. 
Additionally, WGS of another 1,018 individuals at 30x coverage was obtained through Illumina, 406 
through the Illumina CASAVA pipeline and 612 through the Illumina Isaac pipeline, all sequences were 
aligned to the hg19 reference genome. For samples sequenced by Complete Genomics, genotypes were 
available per individual in the Complete Genomics proprietary genotype format. Using Complete Genomics 
Analysis Tools 1.8.0 genotypes were converted to VCF format. For samples sequenced by Illumina, 
genotypes were available for each individual in VCF format. Samples were first merged into three multi-
sample VCF files corresponding to their major platform (Complete Genomics, Illumina CASAVA, Illumina 
ISAAC). Metadata associated with each sample/variant differed across each platform and was incompatible 
for merging VCF files between platforms, accordingly each platform VCF file was converted to PLINK 
format and then combined in PLINK (version 1.90b3m) (22, 23). Variants were assumed to be homozygous 
reference in samples that did not have a genotype call in the sample VCF file for that variant. Variants were 
restricted to biallelic autosomal SNVs. Indel variation was excluded from analysis on the basis of high 
variability in calling and nomenclature across platforms causing incompatibilities in the merging of indels. 
In total 37,819,860 autosomal SNVs were identified and 19,247,876 (51%) were present in the entire dataset 
with five or more allele copies. Samples sequenced by Illumina were also genotyped by Illumina on 
Omni2.5 microarrays. Individual level data was merged using GenomeStudio v2011.1, Genotyping module 
v1.9.4 to combine each version of the Omni2.5 microarrays. PLINK (22, 23) was then used to merge 
variants across array versions and subset to autosomal variants only. The final set of Omni2.5 array variants 
was then extracted from the Complete Genomics WGS to create a harmonized set of 1,146,843 Omni2.5 
array based variants. 
 
Identification of deleterious nonsynonymous SNVs 
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 8 
Using ANNOVAR (24) to annotate biallelic SNVs with RefSeq annotations (25) 72,694 nonsynonymous, 
stop gain or stop loss autosomal SNVs were identified. Of these 36,262 variants had CADD (version 1.3) 
deleteriousness prediction scores ≥ 15 (26). Considering only the subset of 1,020 WGS individuals with 
lipidome data used in this research, there were 28,067 SNVs present with 5 or more allele copies that were 
not monomorphic. These 28,067 nonsynonymous potential deleterious variants were scored as the number 
of minor allele copies for use in measured genotype association testing in SOLAR.  
 
Admixture calculation 
The Omni2.5 array variant set was used to calculate population admixture in our cohort using 
ADMIXTURE (27) (version 1.3.0). Variants from our cohort were overlapped with samples from phase 3 
of the 1000 Genomes Project (1KGP) in the EUR, AFR and AMR super populations, creating a merged 
sample set with 1,038,229 variants. Using known pedigree relationships in our SAFHS cohort we subset 
the sample to contain only SAFHS founders and unrelated 1KGP samples. Using PLINK, variants were 
pruned for nominal Hardy-Weinberg equilibrium (P<0.05) and LD pruned (--indep-pairwise 50 10 0.1) to 
a set of 153,388 variants. ADMIXTURE with K=3, under the assumption of three predominant ancestral 
population groups was conducted on this sample set. Admixture components for the remaining SAFHS 
samples were projected onto the population structure learnt from unsupervised clustering of the 1KGP and 
SAFHS founders. This resulted in three clear population groups, corresponding to Caucasian, African and 
Hispanic admixture. The African and Hispanic components were used in all analyses as covariates to 
control for population substructure.  
 
Empirical kinship coefficient estimation 
For empirical kinship calculation, 100,000 variants from the Omni2.5 array variant set were selected at 
random using PLINK. Empirical kinship coefficients were estimated from this variant set following a 
similar approach to that used by Peralta et al. (28), using the IBDLD method (29) (version 3.33). In the 
derivation of an empirical genetic relationship matrix the propagation of inherent measurement 
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 9 
uncertainties into the kinship approximations can led to singular genetic relationship matrices (a brief list 
of other possible causes can be found in VanRaden (2007) (30)). We used our own implementation of the 
alternating projections method described by Higham (2002) (31) to derive the nearest positive semidefinite 
empirical genetic relationship matrix. This procedure yielded genetic relationship matrices that had the 
expected covariance matrix properties. 
 
Statistical analyses 
All statistical analyses were performed in SOLAR (32) (version 8.1.1) and R version 3.4.3. Heritability 
estimates and variant association testing of inverse normalized lipid measurements were calculated in the 
variance components framework of SOLAR including in each analyses the covariates of age, age2, sex, 
age×sex, Hispanic admixture and African admixture. The non-independence between individuals due to 
their genetic relatedness was accounted for in analysis in SOLAR by use of the calculated empirical kinship 
coefficients. Likelihood ratio tests were obtained for genetic variant associations.  
 
siRNA transfection of HepG2 cells 
HepG2 cells were maintained on 3/1 Dulbecco’s Modified Eagle Medium/Nutrient Mixture F12 media 
(Invitrogen, Carlsbad CA) + 10% fetal bovine serum. One day prior to transfection, the cells were 
trypsinized, counted in a Coulter Z1 counter (Beckman Coulter, Brea CA) and seeded at a density of 1×106 
cells/well in 6 well polyD lysine plates (BD Biocoat 354413). Human DEGS1 ON-TARGETplus SMART 
pool (Thermo Scientific Dharmacon L-006675-00), Non-Targeting ON-TARGETplus Control pool 
(Thermo Scientific Dharmacon D-001810-05), and Human GAPDH ON-TARGETplus Control pool 
(Thermo Scientific Dharmcon T-2004-03) were transfected into cells at a final concentration of 200 nM 
using Dharmafect 4 Transfection Reagent. After various hours post-transfection (as indicated), cells were 
collected by scraping into phosphate buffered saline (PBS) and pelleted by centrifugation at 1400 rpm for 
10min; PBS was aspirated and the cell pellets were frozen at -80C. Cell pellets were analyzed for DEGS1 
protein by western blot. 
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Western blot analysis 
HepG2 cells from siRNA DEGS1 knockdown and non-targeting siRNA control treatments were harvested 
for western blot analysis. Protein analysis was performed on cellular lysates utilizing a Pierce BCA protein 
kit (Thermo Fisher Scientific, San Jose CA). Abcam rabbit anti-Degs1 antibody (ab80654) was used as 
primary antibody, and Alexa-Flur 680 anti-Rabbit IgG was used as secondary antibody (Abcam, Cambridge 
MA). Protein expression was visualized using LI-COR infra-red imaging system (LI-COR, Lincoln NE). 
 
CRISPR/Cas9 plasmid construction 
DEGS1(523-541bp)-pCRISPR-OFP construct was generated by inserting the double-stranded 
oligonucleotide, which was created by annealing forward strand oligonucleotide (GTTTGGGGTT-
GATGAACAGGTTTT) and reverse strand oligonucleotide (CTGTTCATCAACCCCAAACCGGTG), 
into GeneArt™ CRISPR Nuclease Vector pCRISPR-OFP according to the manufacture’s instruction 
(Thermo Fisher Scientific, San Jose CA). DEGS1(L175Q) donor-pUC57 construct was created through 
inserting synthetic DNA containing DEGS1(L175Q) donor sequence into pUC57 vector by GenScript. 
Codon modification of the DEGS1(L175Q) donor sequence was completed to create resistance to the 
DEGS1 targeting CRISPR plasmid. Both constructs were confirmed by DNA sequencing. 
 
CRISPR/Cas9 transfection of HepG2 cells 
HepG2 cells were maintained on 3/1 (DMEM/F12) media (Invitrogen, Carlsbad CA) + 10% FBS. One day 
prior to transfection, the cells were trypsinized and passed through a 2µM filter basket. The cells were 
counted in a Coulter Z1 counter (Beckman Coulter, Brea CA) and seeded at a density of 5×106 cells/10 cm 
dish in growth media. After overnight incubation the cells were transfected using 6.0µg DEGS1(523-
541bp)-pCRISPR-OFP and 6.0µg DEGS1(L175Q) donor-pUC57 and Lipofectamine 2000 according to 
manufacturer’s specifications (Invitrogen, Carlsbad CA). The following day, the cells were trypsinized and 
passed through a 2µM mesh. The cells were sorted for expression of OFP and 10 x 96 well plates were 
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seeded at 1 cell/well. Forty clones were grown, and twenty were expanded for sanger sequencing 
confirmation of L175Q target alteration. Of these twenty, four clones with successful integration were 
selected for lipidomic analysis, ten replicates per clone. One additional clone for which the L175Q alteration 
was not successful was selected as the ‘mock’ control for this experiment with ten replicates analyzed.  
 
Cell lipidomics analysis 
HepG2 cells were trypsinized and washed 3X in PBS. After counting, the cell density was adjusted to 2x106 
cells/ml in 2.0mls of PBS. The cells were pelleted at 1500 X g for 10 minutes at 40C. The PBS was aspirated 
and the cell pellet frozen at -80°C until mass spectrometry analysis. LC/ESI/MS/MS analysis of 
dihydroceramides and ceramides was performed using a TSQ Quantum Ultra-triple quadrupole mass 
spectrometer (Thermo Fisher, San Jose CA) interfaced with an Agilent 1100 HPLC (Agilent Technologies, 
Wilmington, DE) and an Xbridge C8 column (2.1 × 30 mm; Waters, Milford, MA). Lipids from serum 
were extracted using one phase extraction (methanol-dichloromethane) with internal standards. 
Quantification was performed using the ratio of analyte to internal standards relative to sphingolipid 
calibration curves.  
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Results 
Variation in ceramide synthesis pathway lipid levels is heritable 
Using variance component modelling in SOLAR (32) we calculated the heritability of each of these 
dihydroceramide and ceramide species, accounting for age, sex, their interactions and measures of 
Amerindian and African ancestry to control for population substructure. Previously we have used known 
pedigrees to construct genetic relationship matrices for use in SOLAR to appropriately handle the non-
independence of related samples. Here we instead estimate empirical kinship coefficients using the IBDLD 
method (identity by descent linkage disequilibrium) between all pairs of individuals to identify distant or 
unknown connections between individuals in the study (29). As previously shown with pedigree-based 
kinship in our complete lipidome sample set of 1,212, (5) here in the subset of 1,020 with WGS (and thus 
empirical kinship estimates) currently available in our cohort we confirm that all 12 lipid species are 
significantly heritable indicating a genetic component to the variation observed (Table S1), prompting 
further investigation of the underlying genetic contribution to this variation.  
 
A rare potentially functional amino acid change variant, DEGS1 L175Q, is associated with 
dihydroceramide levels 
To detect potentially functional genetic variation we focused our search on 28,067 missense and nonsense 
mutations predicted to be highly deleterious using a CADD (26) phred-scaled score threshold of ≥ 15 and 
which occurred 5 or more times in our sample. Using measured genotype association testing in SOLAR 
(32) we identified a highly significant association (p=3.33×10-13) with a rare variant (L175Q, rs191144864, 
chr1:224377720 T>A) in the DEGS1 gene on chromosome 1 influencing the dihydroceramide species 
Cer(d18:0/24:0). This variant is associated with a statistically and biologically significant increase (βSNP = 
1.35 standard deviation units (SDU)) of the mean in heterozygotes. Figure 1 shows the genome-wide results 
for the Cer(d18:0/24:0) associations with these functional variants, adjusted for age, sex, their interactions 
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and Amerindian and African admixture components. Here we have captured enough copies (n = 28 
heterozygotes) of this globally rare variant to achieve a significant association. In our cohort the L175Q 
variant shows additional genome-wide significant associations with increases in other dihydroceramide 
species including Cer(d18:0/22:0) levels (p = 3.13×10-9, βSNP = 1.10 SDU), Cer(d18:0/24:1) levels (p = 
1.77×10-7, βSNP = 0.97 SDU) and total dihydroceramide levels (p = 6.66×10-10, βSNP = 1.14 SDU) (Table 1, 
see Figures S2-S4 for Manhattan plots). Nominal L175Q associations, not genome-wide significant, with 
increases in the smaller chain dihydroceramides Cer(d18:0/16:0) (p = 8.38×10-4, βSNP = 0.61 SDU), 
Cer(d18:0/18:0) (p = 0.007, βSNP = 0.50 SDU), Cer(d18:0/20:0) (p = 6.81×10-4, βSNP = 0.64 SDU) and 
decreased smaller chain ceramide Cer(d18:1/16:0) (p = 0.039, βSNP = -0.36 SDU) were also detected (Table 
1).   
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The DEGS1 L175Q variant has its strongest influence in the de novo synthesis of ceramides pathway 
With the clear effect identified in dihydroceramide levels we accordingly hypothesized that variants 
affecting the function of DEGS1, such as the L175Q variant, would show associations with multiple lipid 
species across pathways containing ceramide. As dihydroceramide is an essential component of the de novo 
ceramide synthesis pathway, we posited that we would observe associations between the L175Q variant 
and levels of lipid species in pathways containing ceramide, including the sphingomyelin pathways and the 
glycosphingolipid pathway in which ceramide is broken down. Figure 2 shows the effect size of L175Q on 
each lipid species from our data in these three ceramide biology pathways. Overall the effect of L175Q is 
most influential in the de novo ceramide synthesis pathway, but also shows nominal associations with 
decreases in total dihexosylceramides, dihexosylceramide 16:0, trihexosylceramide 16:0 and GM3 
ganglioside 18:0 in the glycosphingolipid pathway and sphingomyelin 34:1 in the sphingomyelin pathway. 
These findings are detailed in Table S2. 
 
The DEGS1 L175Q variant affects disease related ceramide ratios and biological indexes of DEGS1 
activity 
We then examined the L175Q variant in the context of established cardiovascular disease related ceramide 
ratios Cer(d18:1/16:0) to Cer(d18:1/24:0), Cer(d18:1/20:0) to Cer(d18:1/24:0), Cer(d18:1/24:1) to 
Cer(d18:1/24:0) (16, 17) and possible biological indexes of DEGS1 activity by calculating the ratios of 
total ceramide to total dihydroceramide, Cer(d18:1/24:0) to Cer(d18:0/24:0) and apoB to Cer(d18:0/24:0). 
Ratios of ceramide to dihydroceramide are an appropriate index of DEGS1 enzymatic activity because of 
the known role of the DEGS1 enzyme in converting dihydroceramide to ceramide. Similarly, our choice of 
plasma apoB as a relevant numerator for a DEGS1 activity index was driven by a desire to introduce an 
independent assay method into the index and the fact that most ceramides are found on apoB containing 
lipoproteins (33). Each ceramide ratio and DEGS1 activity index showed significant associations with the 
L175Q variant (Table 2). For the ceramide ratios, the L175Q variant is modestly associated with decreases 
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in ceramide levels. For the DEGS1 activity indexes, each ratio showed a highly significant association with 
the L175Q variant (Table 2). Corresponding to a decrease in DEGS1 enzymatic activity, biologically large 
decreases were observed in heterozygotes for each index (β = -1.68 SDU for apoB/dihydroceramide, β = -
1.41 SDU for the Cer(d18:1/24:0)/Cer(d18:0/24:0) ratio, β = -1.28 for the total ceramide : total 
dihydroceramide ratio) further supporting functional effect of L175Q. A decrease in DEGS1 function, as a 
result of L175Q, causes a buildup of dihydroceramide and a decrease in ceramide production. Figure 3 
shows the increase in the dihydroceramide Cer(d18:0/24:0) and the decreases in DEGS1 activity indexes 
in carriers of the L175Q variant.  
 
Genetic variants in DEGS1 broadly impact ceramide pathway biology 
Further, we assessed all observed single nucleotide variants (SNVs) in the DEGS1 gene for association with 
lipid species in ceramide pathways, including levels of dihydroceramides, ceramides, 
monohexosylceramide, dihexosylceramide, trihexosylceramide, GM3 gangliosides and sphingomyelins, 
with the L175Q variant included as a covariate in the analysis. In total there were 101 SNVs identified in 
the DEGS1 gene in this cohort. Measured genotype association analysis in SOLAR identified two other 
DEGS1 variants associated with increases in levels of lipids from the de novo ceramide synthesis and 
sphingomyelin pathways each surpassing the Bonferroni p-value threshold for these 101 variants. Results 
showed that an intronic variant, chr1:224379287 A>C rs965873262, with 6 heterozygotes seen in this 
cohort, was associated with large increases in dihydroceramides (Cer(d18:0/24:0), p = 1.35×10-6, βSNP = 
2.01), while a synonymous variant, chr1:224377955 C>A T253T rs759023173, with 8 heterozygotes in this 
cohort, was associated with large increases in sphingomyelins (SM(32:2), p = 6.10×10-5, βSNP = 1.22) (Table 
3). The functionality of these variants is unknown however they did not occur in individuals with the L175Q 
variant and this indicates that variation in DEGS1 more broadly impacts ceramide pathway biology and 
therefore warrants further investigation and replication in other cohorts.  
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The three DEGS1 variants that show associations with the de novo ceramide synthesis pathway in this 
cohort are each rare variants in publicly available population frequency databases with two (L175Q 
rs191144864 and T253T rs759023173) of likely Hispanic ancestry origin. For the L175Q variant, the 
largest frequency database, gnomAD (v2.1.1) (34, 35), contains 382 copies of the L175Q variant in 17,720 
individuals (Latino MAF=0.01087) from the Latino ancestry population and 3 heterozygotes in the ‘Other’ 
ancestry population. This variant is not detected in any other gnomAD population, with the overall total 
MAF in gnomAD = 0.001361. Here in our Mexican American family cohort we detect 28 copies of this 
variant in 1,020 whole genome sequences. For the intronic chr1:224379287 A>C rs965873262 DEGS1 
variant we detect 6 heterozygotes in our cohort while only 4 heterozygotes are observed in 13,388 
individuals in gnomAD, all of whom are of African ancestry, however as this variant is intronic it is not 
well measured by the gnomAD Latino population samples which are primarily from whole exome sequence 
data. Finally, the synonymous chr1:224377955 C>A rs759023173 DEGS1 variant, for which there are 8 
heterozygotes in our cohort, also appears to be Hispanic ancestry-specific with 38 heterozygotes occurring 
in 10,155 Latino individuals from gnomAD (MAF=0.001871). These three variants are independent in our 
cohort, the carriers do not also have a copy of any of the other variants. 
 
In vitro confirmation of siRNA knockdown effects of DEGS1 on lipidomics in HepG2 cells 
To confirm in vitro that an impairment in the function of DEGS1 affects DEGS1 enzymatic activity, as 
measured through the total ceramide : total dihydroceramide ratio, we designed an siRNA experiment to 
knockdown DEGS1 gene expression in HepG2 cells, used as a model of hepatocyte function. Western blot 
analysis after transfection of siRNAs showed a clear decrease in DEGS1 protein levels in siRNA knock 
down cells across a time course of 24 to 96 hours in comparison to non-targeting siRNA control cells 
(Figure S5). We harvested cell lysate at 96 hours and conducted cell based lipidome analysis. Comparison 
of the total ceramide to dihydroceramide ratio in control cells versus DEGS1 siRNA knockdown cells shows 
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a large decrease in DEGS1 activity (Figure 4, p = 0.007), a directional effect that is consistent with that 
observed for L175Q heterozygotes measured in our cohort. 
 
CRISPR/Cas9 funtional confirmation of lipidomic effects of DEGS1 L175Q variant in HepG2 cells 
To assess whether the DEGS1 L175Q variant encodes a functional mutation, we performed a CRISPR/Cas9 
genome editing experiment in HepG2 cells to introduce the L175Q variant in the heterozygous state to 
identify lipidomic effects, through the total ceramide : total dihydroceramide ratio, in a cell culture model 
of hepatocyte function. A western blot confirmed equivalent DEGS1 protein expression levels in each 
modified cell line and the mock control cell line (data not shown). We compared the total ceramide : total 
dihydroceramide ratio, as a measure of DEGS1 activity, between four CRISPR/Cas9 L175Q cell lines (10 
replicates each) and one mock HepG2 cell line that underwent the CRISPR/Cas9 transfection protocol but 
for which the L175Q alternation did not integrate. Figure 5 shows the significant reduction (p = 0.037) in 
DEGS1 activity in clones carrying the L175Q mutation (mean total ceramide : total dihydroceramide = 
17.46) versus the mock control clone (mean total ceramide : total dihydroceramide = 22.27), equating to 
approximately a 22% reduction (0.43 SDU decrease) in DEGS1 activity. These data indicate that the 
DEGS1 L175Q mutation is associated with a partial loss-of-function of the protein in a HepG2 cell 
CRISPR/Cas9 model.  
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Discussion 
Our investigation of the genetic factors underlying phenotypic variation in the levels of ceramide pathway 
lipids has identified a rare protein coding mutation, L175Q, of apparent Hispanic origin, in DEGS1. This 
variant has a large biological consequence on levels of several dihydroceramide species and has a functional 
effect on DEGS1 activity, confirmed through the introduction of the L175Q mutation into HepG2 cells via 
CRISPR/Cas9 genome editing, and subsequent lipidomic analysis. This is the first rare variant identified 
through WGS to have a large biological impact on the ceramide synthesis pathway. This work highlights 
the power of pedigree-based cohort designs for WGS studies and the potential for genetic studies in minority 
populations. 
 
DEGS1 is the key gene within the de novo ceramide synthesis pathway, encoding the fatty acid desaturase 
enzyme responsible for the generation of ceramide from dihydroceramide, by addition of a double bond, in 
the last step of the pathway. Both dihydroceramides and ceramides are also precursor molecules to complex 
sphingolipids, including sphingomyelins (36). Ruangsiriluk et al (2012) found that when DEGS1 was 
silenced in Huh7 cells, a dramatic increase in dihydroceramide levels was observed along with a significant 
reduction in ceramide levels (37). Gene expression analysis of the DEGS1 knockdown cells revealed 
significantly altered cellular functions, including cell replication, cell-to-cell adhesion, organelle migration 
and autophagy. An increase in cholesterol influx and a reduction in cholesterol efflux is also observed in 
cells lacking DEGS1 activity. Ablation of DEGS1 in in vitro and in vivo studies shows that loss of DEGS1 
function impairs both adipogenesis and lipogenesis, and increases oxidative stress (38). Additionally, the 
presence of completely functional DEGS1 is required for the full differentiation of preadipocytes to mature 
adipocytes (38). Interestingly, Holland et al (2007) showed that heterozygous DEGS1 knockout mice have 
normal glucose tolerance but enhanced insulin sensitivity (39), providing a phenotypic link between DEGS1 
function and disease related mechanisms. Each of these findings are the result of the targeted ablation or 
silencing of DEGS1, with no loss of function mutations identified or studied in this gene to date. This study, 
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in contrast to the previous is the first to identify a DEGS1 coding mutation and its effect on the de novo 
ceramide synthesis pathway.  
 
While we did not detect a direct disease based association for carriers of the L175Q variant, likely as a 
result of small sample numbers, we did identify that the L175Q variant had a modest association with 
decreases in three established ceramide ratios connected to cardiovascular disease, suggesting a protective 
effect of this variant for cardiovascular disease. Recently, two publications have reported overt 
neurodegenerative disorders in humans that are compound heterozygous or homozygous for pathogenic 
mutations in DEGS1 (40, 41). While the L175Q variant described here does not appear in either of these 
studies, and the partial loss of function of the L175Q variant has not led to development of these disorders 
in the heterozygous carriers in our cohort, it is interesting to note the extent that dysfunction in sphingolipid 
metabolism can have on human health. 
 
Taken together, and as expected, we see increases in dihydroceramide levels as a result of the L175Q variant 
causing a loss of function of DEGS1 enzymatic activity. This is supported by indices of DEGS1 activity, 
in both human samples and HepG2 cell models, as well as decreases in downstream lipid species that are 
direct and indirect products of the DEGS1 conversion of dihydroceramide to ceramide; further supporting 
those studies investigating the loss of DEGS1 function. In terms of biological effect sizes due to specific 
genetic variants, these observed estimates are moderate to large depending upon their proximity to gene 
action and are consistent with substantial alterations in the lipidomic profiles of L175Q carriers. The L175Q 
variant also shows associations with established cardiovascular risk ceramide ratios, decreasing these ratios 
in line with a functional effect of the L175Q variant.  
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Studies focusing on specific processes such as metabolic stress, oxidative stress, apoptosis and cancer have 
shown that silencing DEGS1 in cells results in a decrease in ceramide and sphingomyelin synthesis, and 
increasing levels of dihydroceramide and sphinganine species. Additionally, DEGS1 knockdown results in 
down-regulation in almost all metabolic biosynthesis pathways, including cell-cycle growth (37, 42). Our 
results support these findings. This is the first example of a rare coding variant affecting the de novo 
ceramide synthesis pathway that has been identified through the combination of WGS and lipidomic 
profiling. Given the importance of dihydroceramide, ceramide and sphingomyelin metabolism in normal 
cellular functions, DEGS1 may prove to be an important gene in a range of disease contexts. 
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Tables 
Table 1: Summary of significant DEGS1 L175Q associations with 
de novo ceramide synthesis pathway lipid species 
Lipid species chi p(SNP) βSNP (SDU) 
Cer(d18:0/24:0) 53.00 3.33×10-13 1.35 
total dihydroceramide levels 38.18 6.66×10-10 1.14 
Cer(d18:0/22:0) 35.10 3.13×10-9 1.10 
Cer(d18:0/24:1) 27.27 1.77×10-7 0.97 
Cer(d18:0/20:0) 11.54 0.000681 0.64 
Cer(d18:0/16:0) 11.16 0.000838 0.61 
Cer(d18:0/18:0) 7.41 0.006494 0.50 
Cer(d18:1/16:0) 4.26 0.039059 -0.36 
 
 at University of Tasm
ania Library, on O
ctober 1, 2019
w
w
w
.jlr.org
D
ow
nloaded from
 
 28 
Table 2. Summary of L175Q associations with ceramide ratios and biological 
indexes of DEGS1 activity. 
Lipid species chi p(SNP) βSNP (SDU) 
Cer(d18:1/16:0) : Cer(d18:1/24:0) 9.89 0.002 -0.59 
Cer(d18:1/20:0) : Cer(d18:1/24:0)  5.54 0.019 -0.44 
Cer(d18:1/24:1) : Cer(d18:1/24:0) 4.61 0.032 -0.41 
ApoB : Cer(d18:0/24:0) (N=987) 69.09 9.39×10-17 -1.65 
Cer(d18:1/24:0) : Cer(d18:0/24:0) 55.73 8.32×10-14 -1.41 
Total ceramide : total dihydroceramide 46.18 1.08×10-11 -1.28 
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Table 3. Additional DEGS1 variants associated with lipids in ceramide pathways. 
Variant Lipid species chi p(SNP) βSNP (SDU) 
chr1:224379287 A>C rs965873262 Total dihydroceramide 20.35 6.45×10-6 1.89 
chr1:224379287 A>C rs965873262 Cer(d18:0/22:0) 23.03 1.60×10-6 2.04 
chr1:224379287 A>C rs965873262 Cer(d18:0/24:0) 23.36 1.36×10-6 2.01 
chr1:224379287 A>C rs965873262 Cer(d18:0/24:1) 14.51 1.39×10-4 1.64 
chr1:224377955 C>A rs759023173 Total sphingomyelin 13.22 2.77×10-4 1.25 
chr1:224377955 C>A rs759023173 SM(32:2) 16.08 6.10×10-5 1.22 
chr1:224377955 C>A rs759023173 SM(34:1) 16.03 6.20×10-5 1.36 
chr1:224377955 C>A rs759023173 SM(41:2) 13.14 2.90×10-4 1.25 
 
 
 
 at University of Tasm
ania Library, on O
ctober 1, 2019
w
w
w
.jlr.org
D
ow
nloaded from
 
 30 
Figure titles and legends 
 
Figure 1. Genome-wide scan for Cer(d18:0/24:0) levels 
Measured genotype association testing in SOLAR of 28,067 nonsynonymous, likely deleterious SNVs for 
Cer(d18:0/24:0) levels identifies a single genome-wide significant (Bonferroni significance level = 
1.781×10-6) association on chromosome 1 in DEGS1 (L175Q, rs191144864, chr1:224377720 T>A). See 
Figure S1 for QQ plot. 
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Figure 2. Effect (βSNP SDU) of L175Q variant on lipid species in the de novo ceramide synthesis, 
glycosphingolipid and sphingomyelin pathways measured in this cohort 
Bars indicate the standard error of βSNP. Table S2 reports the exact values from this figure. Cer(d18:0/X:X) 
indicates dihydroceramide species; Cer(d18:1/X:X) ceramide; HexCer, monohexosylceramide; Hex2Cer, 
dihexosylceramide; Hex3Cer, trihexosylceramide; GM3, GM3 ganglioside; SM, sphingomyelin. 
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Figure 3. Changes in lipid levels in carriers of the DEGS1 L175Q variant  
Box plots showing A) unadjusted Cer(d18:0/24:0) levels (pmol/mL), B) unadjusted ratio of total ceramide 
: total dihydroceramide, and C) unadjusted ratio of Cer(d18:1/24:0) to Cer(d18:0/24:0), and D) unadjusted 
ratio of ApoB to Cer(d18:0/24:0).
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Figure 4. siRNA knockdown of DEGS1 in vitro in HepG2 cells  
Box plots showing the siRNA knockdown of DEGS1 in HepG2 cells shows a decrease in DEGS1 activity, 
measured as the ratio of total ceramide to total dihydroceramide levels. N = 3 for each experimental group, 
Welch two sample t-test p = 0.007.
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Figure 5. CRISPR/Cas9 DEGS1 L175Q genome editing of HepG2 cells 
Box plots showing the loss-of-function effect of the DEGS1 L175Q variant after the CRISPR/Cas9 
genome editing of HepG2 cell lines. Control cells are ten replicates from one HepG2 clone that 
underwent the full CRISPR/Cas9 transfection protocol, without mutation integration. The L175Q HepG2 
clones are from four cell lines where L175Q mutation integration was successful, with ten replicates of 
each clone. Welch two sample t-test p = 0.037.  
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